Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Unveiling proteomic diversity: A quantitative study of antibody drug conjugate and chemotherapy targets in gastroesophageal cancer.
Authors
Sheeno P. Thyparambil
mProbe Inc., Rockville, MD
Sheeno P. Thyparambil , Negin Ghafourian , Robert Heaton , Amanda Strasbaugh , Marya Abebe Melkie , Chung-Jen James Chou , Xuefeng Ling
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Diagnostics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 261)
DOI
10.1200/JCO.2024.42.3_suppl.261
Abstract #
261
Poster Bd #
B19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.
First Author: Sheeno P. Thyparambil
Poster
2020 ASCO Virtual Scientific Program
Proteomic profiling to identify therapeutics targets in glioblastoma (GBM).
First Author: Sheeno P. Thyparambil
Poster
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
First Author: Cristina Larrosa
Poster
2022 ASCO Annual Meeting
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
First Author: Laura Spring